DNA-Altering Enzyme is Essential for Blood Cell Development
News Jun 12, 2013
HDAC3 is a chromatin-modifying enzyme that regulates gene expression, chromatin structure, and genome instability and it has previously been shown to associate with the oncoproteins that drive leukemia and lymphoma. In this issue of the Journal of Clinical Investigation, Scott Hiebert and colleagues at Vanderbilt University examined the role of HDAC3 in the development of blood cells (hematopoiesis) by disrupting its expression in mice. Loss of Hdac3 nearly eliminated all blood immune cells and caused mild anemia. Hiebert and colleagues observed that, in the absence of Hdac3, stem and progenitor cells, which give rise to blood cells, failed to grow normally. These studies identify a role for HDAC3 in stem cell functions and possibly bone marrow failure syndromes, in which the bone marrow fails to produce blood cells.
The full article is published on line in the Journal of Clinical Investigation and is free to view.
5th International Congress on Epigenetics & Chromatin
Aug 22 - Aug 23, 2019
International Conference on e-Health and Healthcare Innovations
May 08 - May 09, 2019
12th International Conference on Cancer Stem Cells and Oncology Research
Jul 18 - Jul 19, 2019
4th Annual Congress on Nanomedicine and Drug Delivery
Apr 04 - Apr 06, 2019